Drugs / Budesonide Formoterol
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 42 trials | ||||||
| Phase 4 | NCT06568445 | Aug 2024 → Apr 2027 expected | asthma | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT03662711 | Nov 2018 → Oct 2022 | chronic obstructive pulmonary disease | Università degli Studi di Ferrara | Terminated | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT06895460 Background | Jun 2025 → Jun 2027 expected | asthma | The First Affiliated Hospital with Nanjing Medical University | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Budesonide formoterol | “Budesonide formoterol” NCT03662711 ↗ |
| Known as | Symbicort 160/4.5 | “Maintenance at initial treatment sequential as-needed therapy with inhaled budesonide-formoterol(Symbicort 160/4.5) ®）” NCT06568445 ↗ |
| Route | Inhaled | “budesonide 160 µg-formoterol 4.5 µg (Symbicort 160/4.5) ®）, administered as one inhalation twice daily” NCT06568445 ↗ |